Deerfield To NitroMed: Not So Fast, Not So Cheap
This article was originally published in The Pink Sheet Daily
Executive Summary
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.